Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases.

Scientific reports - 13 Sept 2021

Lauko Adam, Kotecha Rupesh, Barnett Addison, Li Hong, Tatineni Vineeth, Ali Assad, Patil Pradnya, Mohammadi Alireza M, Chao Samuel T, Murphy Erin S, Angelov Lilyana, Suh John H, Barnett Gene H, Pennell Nathan A, Ahluwalia Manmeet S

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICIs within 90 days of NSCLCBM diagnosis (ICI-90) and compared them to patients who never received ICIs (no-ICI). We reviewed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lung Neoplasms

Share to Multivariate Analysis

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 34518623
DOI: 10.1038/s41598-021-97566-z
PMCID: PMC8438061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases.PMID 34518623Read ↗

Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis.Semantic proximity Read ↗

Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.Semantic proximity Read ↗

A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.Semantic proximity Read ↗

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.Semantic proximity Read ↗

The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.Semantic proximity Read ↗

Clinical outcomes and predictive factors of immunotherapy efficacy in non-small cell lung cancer brain metastases: A comparative studySemantic proximity Read ↗

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.Semantic proximity Read ↗

In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data.Semantic proximity Read ↗

Differential Benefit of Immune Checkpoint Blockade by<i>KRAS</i>Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish CohortSemantic proximity Read ↗

Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.Semantic proximity Read ↗

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.Semantic proximity Read ↗

Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.